New antibody shows promise against treatment-resistant cancers

Researchers at King's College London have developed a new antibody treatment, IgE, that shows promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. This approach differs from existing therapies by activating immune cells in a unique way. In tests on mice, IgE antibodies effectively targeted HER2-expressing cancer cells, slowing tumor growth. This suggests potential for patients who do not respond to current treatments, as IgE can reprogram the immune environment to attack tumors. The study indicates that IgE could become a new therapy option for HER2-positive cancers. Researchers believe that with further development, this treatment could be available for human use within 3-5 years.